Charles Schwab Investment Management Inc Crispr Therapeutics Ag Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 669,192 shares of CRSP stock, worth $36.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
669,192
Previous 653,023
2.48%
Holding current value
$36.8 Million
Previous $40.9 Million
11.58%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding CRSP
# of Institutions
551Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$449 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$431 Million0.11% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$180 Million0.16% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$180 Million2.23% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$149 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.29B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....